I don't see it. The narrative is that the drug is a CCR5 antagonist that blocks HIV from entering cells, and doesn't have serious side effects and can be used with other therapies.
If this was true this drug would be a VERY big deal in the HIV world. Most HIV-1 strains need to bind to the CCR5 receptor in CD4 T cells in order to establish infection, although they can later mutate inside the host so they don't need do. In fact, the only natural immunity ever observed to HIV is a very rare mutation to CCR5.
This drug has been languishing in trials for 10+ years. If it lived up to the narrative it should be front line HIV therapy. Something isn't adding up.
As far as trials with COVID-19 go, CCR5 is an important chemokine receptor involved in the immune response. So it appears the company is just trying out this drug as a general immune suppressant, as runaway immune response seems to be involved in pathology of serious COVID disease. But there are a lot of immune suppressant drugs, so I don't see why this one would be especially effective.
I wish you good luck with your gambool. But I just don't see it. I would guess this is a pump and dump scheme.
Edit: I just read today's press clippings from today and I guess the company is implying they have discovered a novel reason a CCR5 antagonist would effect SARS-COV2 directly. To date there is no proposed reason a CCR5 antagonist would directly effect the disease process that I know of. FWIW, CCR5 is expressed mainly on immune cells, which are not even cells that SARS-COV2 infects primarily, so I don't have a clue what mechanism they are claiming to have discovered. So I guess we will have to just wait and see what they have to say.






Reply With Quote